Skip to main content
Evidence Snapshot

Aryl hydrocarbon receptor

CHEMBL3201 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:50:59Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3201
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Aryl hydrocarbon receptor as ChEMBL target CHEMBL3201, mapped to UniProt P35869. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Aryl hydrocarbon receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3201
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P35869
Aryl hydrocarbon receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Aryl hydrocarbon receptor matters

As of 2026-09-13

Aryl hydrocarbon receptor is reviewed as Aryl hydrocarbon receptor (UniProt P35869); Aryl hydrocarbon receptor shows approved-linked disease relevance led by psoriasis. 1 more disease program remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 1 approved drug, 755 compounds, and 246 assays, with lead potency reaching pChEMBL 11.0.

Disease context
psoriasis

Aryl hydrocarbon receptor shows approved-linked disease relevance led by psoriasis. 1 more disease program remain visible in the same review block. 1 linked drug keep the rationale reviewable. 1 additional disease programs remain visible in the same card. Linked drugs include TAPINAROF.

Start review with psoriasis because it currently carries approved-linked support. Linked drugs include TAPINAROF. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 1 approved drug, 755 compounds, and 246 assays for this target. The dominant activity type is EC50. CHEMBL5289699 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL5289699 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
1 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Aryl hydrocarbon receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P35869, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why psoriasis is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

755
Total Compounds
246
Total Assays
1
Approved Drugs
IC50: 31.0, KI: 38.0, EC50: 413.0, KD: 6.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5289699
 11.0 EC50 —
No preferred name
CHEMBL5203882
 10.5 EC50 —
No preferred name
CHEMBL472031
 10.2 Kd —
No preferred name
CHEMBL5285977
 10.0 EC50 —
No preferred name
CHEMBL4580482
 9.9 Kd —

Approved Drugs

Structure Compound First Approval
TAPINAROF
CHEMBL259571
 2022
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:50:59Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3201